S
Sheetal Patel
Researcher at Genentech
Publications - 25
Citations - 872
Sheetal Patel is an academic researcher from Genentech. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 13, co-authored 22 publications receiving 375 citations. Previous affiliations of Sheetal Patel include Ottawa Hospital Research Institute & University of British Columbia.
Papers
More filters
Journal ArticleDOI
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
David Miles,Joseph Gligorov,Fabrice Andre,David Cameron,Andreas Schneeweiss,C. Barrios,B H Xu,A. Wardley,D. Kaen,L. Andrade,V. Semiglazov,M. Reinisch,Sheetal Patel,Monika Patre,Leilani Morales,S.L. Patel,M. Kaul,T. Barata,Joyce O'Shaughnessy,Q. Zhang,Z. Shao,X. Wang,C. Geng,X. Yan,Z. Tong,K. Shen,Y. Yin,T. Sun,J. Yang,J. Feng,M. Yan,Y. Wang,Q. Liu,S. Zhang,M. De Laurentiis,A. Santoro,V. Guarneri,M. Colleoni,C. Natoli,L. Cortesi,S. Placido,L. Gianni,F. Ferrau,L. Livi,A. Zambelli,L. Del Mastro,G. Tonini,F. Montemurro,G. Bianchi,R. Pedersini,S. Prete,G. Allegrini,G. Naso,P. Vici,D. Loirat,A. Mailliez,F. Priou,O. Tredan,F. Dalenc,C. Perrin,M. Timar David,N. Dohollou,L. Teixeira,F. Brocard,A. Arnaud,S. Delaloge,J.-P. Spano,L. Mansi,F. Damian,J. Pedrini,S. Aleixo,R. Hegg,R. Junior,M. Schmidt,C. Wenzel,E.-M. Grischke,M. Just,N. Harbeck,C. Schumacher,U. Peters,D. Fischer,H. Forstbauer,R. Liersch,E. Warner,N. Bouganim,C. Doyle,J. Price Hiller,T. Vandenberg,M. Pavic,A. Robinson,G. Roldan Urgoiti,N. Califaretti,A. Alacacioglu,M. Gumus,B. Yalcin,I. Cicin,F. Kose,K. Uygun,M. Kaplan,E. Cubukcu,M. Harries,D. Doval,S. Gupta,P. Mohapatra,S. Chatterjee,N. Ghadyalpatil,M. Singhal,S. Nag,A. Agarwal,I. Wolf,E. Gal Yam,R. Yerushalmi,T. Peretz,G. Fried,N. Ben Baruch,D. Katz,E. Hamilton,F. Kayali,A. Brufsky,M. Telli,G. Wright,R. Oyola,T. Rakowski,S. Graff,S. Tjulandin,A. Aparicio,M. Ruiz Borrego,L. Merino,J. Guerra Martinez,E. Lopez,T. Yamashita,S. Ohtani,K. Inoue,Y. Ito,N. Niikura,T. Nakayama,Y. Sagara,Y. Yanagita,Y. Kamada,K. Kaneko,A. Nervo,A. Eniu,M. Schenker,P. Priester,B. Melichar,M. Zimovjanova,P. Sormova,J. Sufliarsky,M. Kakalejcik,R. Belbaraka,H. Errihani,D. Le Than,D. Pham,G. Aravantinos,C. Papadimitriou,G. Koumakis,C. Papandreou,P. Podolski,K. Tabane +158 more
TL;DR: In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in the intention-to-treat (ITT) and programmed death-ligand 1 (PD-L1)-positive populations, and a clinically meaningful overall survival (OS) effect in PD-L 1-positive aTNBC as discussed by the authors.
Journal ArticleDOI
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
Leisha A. Emens,Sylvia Adams,Carlos H. Barrios,Véronique Diéras,H. Iwata,Sherene Loi,Hope S. Rugo,Andreas Schneeweiss,EP Winer,Sheetal Patel,Volkmar Henschel,A. Swat,M. Kaul,Luciana Molinero,S.Y. Chui,Peter Schmid +15 more
TL;DR: The final overall survival (OS) and safety of that study as per the prespecified analysis plan was reported in this article, where patients were randomized to nP 100 mg/m2 (days 1, 8, and 15 of a 28-day cycle) with atezolizumab 840 mg (AÂ+ nP) or placebo (PÂ + nP; days 1 and 15), until progression or unacceptable toxicity.
Journal ArticleDOI
Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop
Paul G. Kluetz,Bindu Kanapuru,Steven Lemery,Laura Lee Johnson,Mallorie H. Fiero,Karen Arscott,Yolanda Barbachano,Ethan Basch,Michelle Campbell,Joseph C. Cappelleri,David Cella,Charles S. Cleeland,Corneel Coens,Selena R. Daniels,Crystal S. Denlinger,Dianne L. Fairclough,James R. Hillard,Lori M. Minasian,Sandra A. Mitchell,Daniel O’Connor,Sheetal Patel,Eric H. Rubin,Anna Rydén,Katherine M. Soltys,Rajeshwari Sridhara,Gita Thanarajasingam,Galina Velikova,Stephen Joel Coons +27 more
TL;DR: A cosponsored workshop on the use of PRO measures to inform the assessment of safety and tolerability in cancer clinical trials and potential approaches to the patient-reported assessment of an investigational drug's overall side effect burden was convened.
Journal ArticleDOI
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer
Sylvia Adams,Véronique Diéras,Carlos H. Barrios,EP Winer,Andreas Schneeweiss,H. Iwata,Sherene Loi,Sheetal Patel,Volkmar Henschel,S.Y. Chui,Hope S. Rugo,Leisha A. Emens,Peter Schmid +12 more
TL;DR: A + nP as first-line treatment for mTNBC delayed progression without compromising patients' day-to-day functioning or HRQoL or worsening treatment symptoms.
Journal ArticleDOI
IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
Leisha A. Emens,Sylvia Adams,Carlos H. Barrios,Véronique Diéras,H. Iwata,Sherene Loi,Hope S. Rugo,Andreas Schneeweiss,EP Winer,Sheetal Patel,V. Henschel,A. Swat,M. Kaul,Luciana Molinero,S.Y. Chui,Peter Schmid +15 more
TL;DR: While OS differences for A + nP vs P - nP in the IMpassion130 ITT population were not statistically significant, precluding formal testing, clinically meaningful OS benefit was observed in PD-L1+ pts and A +nP remained safe and tolerable with longer follow-up.